Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Jin Won Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1357-7015; OpenAlex author ID A5100652723. Sources: OpenAlex.

Their work

Papers
12 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 3 papers · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 12

  1. PAK4 orchestrates dual transcriptional and post-translational repression of E-cadherin to promote epithelial-to-mesenchymal transition and invasiveness in panc… Last author DOI 10.1038/s41417-026-01091-y↗
  2. Analysis of Recent Improvement of Survival Outcomes in Patients with Pancreatic Cancer Who Underwent Upfront Surgery. Co-author DOI 10.5009/gnl230303↗
  3. NGS-based targeted gene mutational profiles in Korean patients with pancreatic cancer. Co-author DOI 10.1038/s41598-022-24732-2↗
  4. Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX. Co-author DOI 10.3390/jpm11020083↗
  5. A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer. Co-author DOI 10.7150/jca.50514↗
  6. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry. Co-author DOI 10.1097/coc.0000000000000730↗
  7. Sex Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX Co-author DOI 10.21203/rs.3.rs-33720/v1↗
  8. Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. First author DOI 10.1016/j.ejca.2017.02.010↗
  9. Prognostic value of p21-activated kinase 4 in resected pancreatic cancer. First author DOI 10.1111/apm.12705↗
  10. Early versus delayed initiation of adjuvant treatment for pancreatic cancer. Co-author DOI 10.1371/journal.pone.0173960↗
  11. p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines. First author DOI 10.4143/crt.2014.054↗
  12. Metastatic testicular tumor presenting as a scrotal hydrocele: An initial manifestation of pancreatic adenocarcinoma. First author DOI 10.3892/ol.2014.2009↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jin‐Hyeok Hwang · 8 shared papers, 2017–2024 · strength 0.96
  2. Jaihwan Kim · 6 shared papers, 2017–2024 · strength 0.75
  3. Jong-Chan Lee · 5 shared papers, 2017–2024 · strength 0.66
  4. Kwangrok Jung · 4 shared papers, 2020–2024 · strength 0.64
  5. Jinkook Kim · 3 shared papers, 2020–2021 · strength 0.36
  6. Yoo‐Seok Yoon · 2 shared papers, 2017–2024 · strength 0.27
  7. Ho‐Seong Han · 2 shared papers, 2017–2024 · strength 0.27
  8. Zev A. Wainberg · 1 shared paper, 2026 · strength 0.22
  9. Kui‐Jin Kim · 1 shared paper, 2026 · strength 0.22
  10. Se Hyun Kim · 1 shared paper, 2026 · strength 0.22
  11. Jun Suh Lee · 1 shared paper, 2024 · strength 0.21
  12. Jae Hyup Jung · 1 shared paper, 2024 · strength 0.21
  13. Hyoung Woo Kim · 2 shared papers, 2017 · strength 0.16
  14. Hunho Song · 1 shared paper, 2021 · strength 0.11
  15. Boram Han · 1 shared paper, 2021 · strength 0.11
  16. Dae Young Zang · 1 shared paper, 2021 · strength 0.11
  17. Jung Han Kim · 1 shared paper, 2021 · strength 0.11
  18. Byoung Yong Shim · 1 shared paper, 2021 · strength 0.11
  19. Dong Woo Shin · 1 shared paper, 2020 · strength 0.10
  20. Woo Jin Lee · 1 shared paper, 2020 · strength 0.10
  21. Sang Myung Woo · 1 shared paper, 2020 · strength 0.10
  22. Hyun Kyung Chang · 2 shared papers, 2014–2015 · strength 0.09
  23. Jong-chan Lee · 1 shared paper, 2017 · strength 0.09
  24. Young Hoon Kim · 1 shared paper, 2017 · strength 0.07
  25. Sehhoon Park · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.